AFFILIATIONS
1 Henri-Mondor Hospital, Assistance Publique Hôpitaux de Paris, Créteil, France
2 Henri-Mondor Hospital, Assistance Publique Hôpitaux de Paris, Créteil, France
3 Dijon University Hospital, Dijon, France
4 IUCT-Oncopole, CHU de Toulouse, Toulouse, France, Toulouse, France
5 CH Sud Francilien, Corbeil Essonne, France
6 Amiens University Hospital, Amiens, France
7 Nancy University hospital, Nancy, France
8 Marseille University hospital, Marseille, France
9 Toulouse University Hospital, Toulouse, France
10 Nantes University hospital, Nantes, France
11 Saint-Antoine University hospital, AP-HP, Paris, France
12 Saint Etienne University Hospital, Saint Etienne, France
13 CHRU de Brest – Hôpital de la Cavale Blanche, Université de Brest, Brest, France, Brest, France
14 Bordeaux University hospital, Bordeaux, France
15 Bordeaux University hospital, Bordeaux, France
16 Hospices Civils de Lyon, Université Claude Bernard Lyon, Lyon, France
17 Hopital Foch, Surenes, France
18 CH Argenteuil, Argenteuil, France
19 CHU ROUEN, Rouen, France
20 CHU CAEN, CAEN, France
21 CH Avignon, Avignon, France
22 Kremlin Bicêtre Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
23 Hôpital européen Georges-Pompidou (HEGP) , Assistance Publique Hôpitaux de Paris, Paris, France
24 CHU d’Angers, Angers, France
25 Henri-Mondor Hospital, Assistance Publique Hôpitaux de Paris, Créteil, France
26 Henri-Mondor Hospital, Assistance Publique Hôpitaux de Paris, Créteil, France
27 Saint Louis University hospital, Assistance Publique Hopitaux de Paris, Paris, France
28 Cochin Hospital, Assistante publique Hôpitaux de Paris, Paris, France
29 Hôpital de Vannes, Vannes, France
30 CENTRE HOSPITALIER INTERCOMMUNAL DE POISSY SAINT GERMAIN, POISSY SAINT GERMAIN, France
31 Department of Internal Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France., Lyon, France
32 URC, Hôpital Henri-Mondor, AP-HP, Université Paris-Est Créteil (UPEC), Créteil, France, Créteil, France
33 URC, Hôpital Henri-Mondor, AP-HP, Université Paris-Est Créteil (UPEC), Créteil, France, Créteil, France
34 Département d'Épidémiologie et Santé Publique, Hôpital Henri-Mondor, AP-HP, Université Paris-Est Créteil (UPEC), Créteil, France, Créteil, France
35 Dijon University Hospital, Dijon, France
36 Henri-Mondor Hospital, Assistance Publique Hôpitaux de Paris, Créteil, France
37 Hôpital Saint-Louis, APHP, Université de Paris Cité, Paris, France
38 Henri-Mondor Hospital, Assistance Publique Hôpitaux de Paris, Créteil, France
ABSTRACT
Background and Objective
Patients with immune thrombocytopenia (ITP), who are profoundly thrombocytopenic and have active bleeding manifestations are at risk of life-threatening hemorrhage and require prompt rescue therapy. Intravenous immunoglobulin (IVIg) plus prednisone is the current standard treatment in this setting but is associated with high costs, limited availability of IVIg, and potential adverse events. High-dose dexamethasone (DXM) has shown efficacy in ITP, and we hypothesized that it could be a non-inferior alternative to IVIg plus prednisone in patients with moderate to severe bleeding manifestations.
Methods
We conducted a prospective, randomized, open-label, multicenter, phase III non-inferiority trial (NCT04968899) with a 1:1 allocation ratio between two parallel arms: IVIg+prednisone versus DXM. The DXM arm received oral dexamethasone (Neofordex®) 40 mg once daily on days 1–4, with an optional second 4-day course between days 10 and 21. The IVIg+prednisone arm received IVIg 1 g/kg on days 1–2 plus prednisone 1 mg/kg/day for 21 days. Key inclusion criteria were age 18 to 80 years, diagnosis of ITP according to standard criteria regardless of disease duration (newly diagnosed or relapsed), platelet count ≤20 × 109/L, and cutaneous and/or mucosal bleeding manifestations. Patients with ongoing anticoagulation treatment or life-threatening bleeding were excluded. Randomization was stratified by age, duration of ITP (chronic vs non-chronic) and bleeding severity as assessed by the modified French Bleeding score without age. The primary endpoint was time to initial response within the first 5 days. Initial response was defined as a platelet count ≥30 × 109/L with at least a doubling from baseline, in the absence of new bleeding and without additional ITP-directed therapy. Complete response was defined as a platelet count ≥100 × 10?/L, without new bleeding or additional ITP-directed therapy.
Results.
Between April 2022 and March 2026, 272 patients were randomized across 33 centers. After one consent withdrawal, 271 patients were included in the intention-to-treat analysis (135 IVIg+prednisone, 136 DXM). Baseline characteristics were well balanced between groups, with a median age of 51 years [33-67,25], a median platelet count of 6 × 109/L [3-11.75], a median modified French bleeding score of 6 (IVIg+prednisone) and 7 (DXM) [4–8], and approximately 70% of patients with newly diagnosed ITP. The primary endpoint did not meet the predefined non-inferiority criterion for DXM: by day 5, response was achieved in 114/135 patients (84.4%) receiving IVIg+prednisone versus 98/136 patients (72.1%) receiving DXM, corresponding to an absolute difference of −12.3% (95%CI, −23.0% to −3.0%). Time-to-response analysis confirmed significantly slower responses with DXM (HR, 0.60; 95% CI, 0.46–0.78; P<0.001), with consistent findings in the per-protocol analysis. Complete response at day 5 also favored IVIg+prednisone (69.6% vs 38.2%; P<0.0001), with differences emerging as early as day 2. The French bleeding score from Day 1 to Day 5 and the occurrence of new bleeding did not differ between groups. Thirty of the 136 patients (22%) from the DXM arm received an additional protocol-specified cycle of DXM. Overall, rescue therapy was required more frequently in the DXM arm than in the IVIg+prednisone arm (30.1% vs 5.2%). Response at day 28 remained higher with IVIg+prednisone than with DXM (63.7% vs 43.4%; P=0.002). Thirty-four patients experienced 50 serious adverse events (24 in 18 patients in the IVIg+prednisone arm and 26 in16 patients in the DXM arm).
Conclusion
In this randomized trial, DXM was inferior to IVIg plus prednisone for early platelet response in adult patients with ITP and active bleeding. Although no difference was observed between both groups in the occurrence of new bleeding events between day 1 and day 5, IVIg plus prednisone resulted in a faster and more sustained platelet response and less need for extra rescue treatments by day 28. These findings support IVIg plus prednisone as the preferred first-line treatment for ITP patients with severe bleeding manifestations.